Summary
Bristol-Myers Squibb (BMY) reported strong third-quarter and year-to-date results for 2016, driven significantly by robust growth in key products like Opdivo and Eliquis. Total revenues increased by 21% for the quarter and 16% for the nine months, reaching $4.9 billion and $14.2 billion, respectively. Net earnings attributable to BMS saw a substantial rise to $1.2 billion for the quarter and $3.6 billion for the nine months, leading to diluted EPS of $0.72 and $2.12, respectively. The company also enhanced its financial flexibility by increasing its cash and marketable securities position to $8.6 billion and approving a new $3.0 billion share repurchase program. While the company reported disappointing Phase III results for Opdivo in first-line non-small cell lung cancer (CheckMate-026), it continues to explore combination therapies and other indications for its immuno-oncology portfolio. BMS also continued its strategic acquisitions, including Cormorant Pharmaceuticals and Padlock Therapeutics, to bolster its pipeline in oncology and autoimmune diseases. The company is also undergoing an operating model evolution to streamline operations and focus investments, which is expected to incur restructuring charges but maintain non-GAAP operating expenses.
Financial Highlights
56 data points| Revenue | $4.92B |
| Cost of Revenue | $1.30B |
| Gross Profit | $3.62B |
| R&D Expenses | $1.14B |
| SG&A Expenses | $1.14B |
| Operating Expenses | $3.36B |
| Interest Expense | $42.00M |
| Net Income | $1.20B |
| EPS (Basic) | $0.72 |
| EPS (Diluted) | $0.72 |
| Shares Outstanding (Basic) | 1.67B |
| Shares Outstanding (Diluted) | 1.68B |
Key Highlights
- 1Total revenues surged by 21% to $4.9 billion in Q3 2016 compared to the prior year, driven by strong performance in key products.
- 2Net earnings attributable to BMS increased significantly to $1.2 billion in Q3 2016, representing a substantial improvement over the prior year's $706 million.
- 3Diluted EPS rose to $0.72 in Q3 2016, up from $0.42 in Q3 2015, reflecting improved profitability.
- 4Opdivo and Eliquis were major growth drivers, with Opdivo sales increasing over 200% year-over-year for the quarter and Eliquis sales up 90%.
- 5The company completed strategic acquisitions of Cormorant Pharmaceuticals and Padlock Therapeutics to strengthen its pipeline in oncology and autoimmune diseases.
- 6BMY announced an operating model evolution expected to cost between $1.5 to $2.0 billion in restructuring charges, aimed at improving focus and agility.
- 7The company's cash, cash equivalents, and marketable securities stood at $8.6 billion as of September 30, 2016, providing significant financial flexibility.